NCT03091556 is a clinical trial in Drug-Induced Liver Injury, sponsored by Beijing 302 Hospital.

Who is sponsoring NCT03091556?

NCT03091556 is sponsored by Beijing 302 Hospital.

What condition does NCT03091556 study?

NCT03091556 studies Drug-Induced Liver Injury.

Is NCT03091556 still recruiting?

NCT03091556 is currently status unknown. Last updated 27 March 2017.

Last reviewed 2017-03-27 · How we verify

NCT03091556

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.

Status unknown Last updated 27 March 2017

What this trial tests

trial in Drug-Induced Liver Injury in 1,000 participants. Status unknown.

Timeline

25 March 2017

Primary endpoint
31 December 2017

31 December 2017

Quick facts

Lead sponsor	Beijing 302 Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	25 March 2017
Primary completion	31 December 2017
Estimated completion	31 December 2017
Sites	1 location across China

Conditions studied

Drug-Induced Liver Injury — all drugs for Drug-Induced Liver Injury →

Sponsor

Beijing 302 Hospital

Who can join

Adults 18 to 70, any sex, with Drug-Induced Liver Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective registry study to surveil early liver injuries caused by Xianlin Gubao Pill (XLGB Pill) through a non-intervention observational way. And attempt to establish a predictive model to screen susceptibilities to XLGB Pill.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Drug-Induced Liver Injury

Currently open trials in the same condition.

NCT06872372 — Role of N-Acetylcysteine in Non-Acetaminophen-Induced Acute Liver Failure · NA · active not recruiting
NCT04964310 — Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study · recruiting

Other Beijing 302 Hospital trials

Trials by the same sponsor.

NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03091556 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
Last refreshed: 27 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03091556.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing